By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NOXXON Pharma AG 

Max-Dohrn-Strasse 8-10

Berlin    10589  Germany
Phone: 49-30-726247-0 Fax: 49-30-726247-225


SEARCH JOBS


Industry
Pharmaceutical

Segment
Drug Discovery





Company News
NOXXON Pharma AG Appoints Aram Mangasarian As CEO 7/14/2015 9:16:46 AM
First Data From NOXXON Pharma AG’s NOX-H94 (Lexaptepid Pegol) Clinical Trial In ESA-Hyporesponsive Dialysis Patients Reported At ERA-EDTA Conference 5/29/2015 9:03:19 AM
NOXXON Pharma AG Release: Nature Communications Publications On The First X-Ray Crystal Structures Of Spiegelmers Bound To Protein Targets 4/23/2015 9:43:02 AM
New Addition To NOXXON Pharma AG Supervisory Board Brings Significant U.S. Public Market Expertise 12/10/2014 8:55:20 AM
NOXXON Pharma AG Release: Phase IIa Results For Spiegelmer Olaptesed Pegol (NOX-A12) In MM And CLL At 2014 American Society of Hematology Conference 12/5/2014 1:31:25 PM
NOXXON Pharma AG Spiegelmer® Receives FDA Orphan Drug 9/23/2014 8:58:58 AM
NOXXON Pharma AG Expands Management Team By Appointing Don Munoz As Chief Financial Officer 9/18/2014 9:29:20 AM
Two Presentations At International Conferences Of Preclinical Data On NOXXON Pharma AG’s anti-C5a Spiegelmer®, A Potential Drug In Pneumococcal Pneumonia-Induced Sepsis 9/4/2014 9:32:31 AM
NOXXON Pharma AG Initiates Phase IIa Study Of Anti-Hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) In Dialysis Patients With EPO-hyporesponsive Anemia 7/31/2014 9:26:41 AM
NOXXON Pharma AG Presents Updates On Phase II Studies With Olaptesed Pegol (NOX-A12) In CLL And MM And Lexaptepid Pegol (NOX H94) In Anemic Cancer Patients 6/13/2014 9:55:04 AM
12345
//-->